StockWatch
·
HomeLiveWeekly
Biotechnology: Biological Products (No Diagnostic Substances)
Business UpdateApr 29, 2026, 07:02 AM

OKYO CEO to Present at Eyecelerator; Leadership at ARVO Meeting

AI Summary

OKYO Pharma Ltd announced its CEO will present at Eyecelerator, and company leadership will participate in the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Denver, Colorado. These engagements offer opportunities for the company to interact with the scientific and medical community.

Key Highlights

  • OKYO Pharma CEO to present at Eyecelerator.
  • Company leadership to participate in the ARVO Annual Meeting in Denver, Colorado.
  • Events provide platforms for engagement with the scientific and medical community.
View SEC Filing
OKYO
Biotechnology: Biological Products (No Diagnostic Substances)
OKYO Pharma Ltd

Price Impact

More from OKYO

USFDA12h ago

OKYO Pharma Gets Positive FDA Feedback for Urcosimod Phase 3 Trial

USFDA12h ago

OKYO Pharma gets FDA alignment for single-trial Phase 3 urcosimod

Business Update1d ago, 7:06 AM

OKYO Pharma to participate in Piper Sandler Ophthalmology Symposium

More in Business Update

NOA2h ago

NACG Awarded Five-Year, $135M Heavy Equipment Services Contract

NOA2h ago

North American Construction Group Subsidiary Wins $135M Contract

SR3h ago

Spire Recasts FY25 Financials; Discontinued Ops & Segment Changes